Benjamin Hallisey

Abstract 496: Oncolinkage: Discovery of tumor-selective surface targets for cancer therapy.

McKensie Collins, Benjamin Hallisey, Andrew Astley, Rick Nicoletti et autres

Abstract Cancer therapeutics such as CAR T, Radioligand , ADC, and Bispecifics are all reliant on targeting cancer-selective surface proteins. A major limitation to these tethered killing strategies is the lack of targets that are exclusively expressed on tumor cells and not …

us (code pays fourni par la source)

Abstract 4533: Discovery and characterization of CARs against novel, highly selective solid tumor targets identified using the Oncolinkage platform

McKensie Collins, Benjamin Hallisey, Andrew Astley, Murray O. Robinson

Abstract CAR T cell therapy has demonstrated remarkable efficacy in treating hematologic malignancies. However, these therapies have been largely unsuccessful in solid tumors, which account for approximately 90% of cancer diagnoses. A critical obstacle to developing CAR T cell therapies for solid …

us (code pays fourni par la source)

Durable Multiplex Epigenetic Editing for Generation of Allogeneic CAR T without Chromosomal Rearrangements

Jamie L. Schafer, Justin D. Trombley, Benjamin Hallisey, Kunza Ahmad et autres

CAR T therapies have provided significant breakthroughs for patients with CD19+ malignancies and multiple myeloma, but a major limitation is the need for individualized manufacturing of autologous T cells, increasing the cost and reducing the availability of these life-saving drugs. An allogeneic …